Phosphocol Side Effects Center

Last updated on RxList: 6/8/2017
Phosphocol Side Effects Center

Medical Editor: John P. Cunha, DO, FACOEP

Last reviewed on RxList 8/18/2015

Phosphocol P 32 (chromic phosphate P 32) Suspension is a diagnostic agent used for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. The brand name Phosphocol P 32  is discontinued, but generic versions may be available. Common side effects of Phosphocol P 32 (chromic phosphate P 32) include: 

The suggested dose range of Phosphocol P 32 employed in the average patient (70 kg) is: Intraperitoneal instillation: 370 to 740 megabecquerels (10 to 20 millicuries); Intrapleural instillation: 222 to 444 megabecquerels (6 to 12 millicuries); Doses for interstitial use should be based on estimated gram weight of tumor, about 3.7 to 18.5 MBq/gm (0.1 to 0.5 mCi/gm). Phosphocol P 32 may interact with other drugs. Tell your doctor all medications and supplements you use. Phosphocol P 32 is generally not recommended for use during pregnancy or while breastfeeding. Tell your doctor if you are pregnant or breastfeeding before starting treatment with Phosphocol P 32.

Our Phosphocol P 32 (chromic phosphate P 32) Suspension Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Skin Cancer Symptoms, Types, Images See Slideshow
Phosphocol Professional Information


Untoward effects may be associated with use of chromic phosphate P 32. These include transitory radiation sickness, bone marrow depression, pleuritis, peritonitis, nausea and abdominal cramping. Radiation damage may occur if accidentally injected interstitially or into a loculation.

Post-marketing Experience

The following adverse reactions associated with the use of Phosphocol P 32 have been identified during post approval use:

Leukemia in Children (see WARNINGS)

Radiation injury (necrosis and fibrosis) to the small bowel, cecum, and bladder following administration of P 32 into the peritoneal cavity.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Read the entire FDA prescribing information for Phosphocol (Phosphocol)

© Phosphocol Patient Information is supplied by Cerner Multum, Inc. and Phosphocol Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors